Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Capital Expenditures (2016 - 2025)

Avanos Medical (AVNS) has disclosed Capital Expenditures for 13 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 193.24% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.6 million through Dec 2025, up 464.29% year-over-year, with the annual reading at $31.6 million for FY2025, 464.29% up from the prior year.
  • Capital Expenditures hit $6.9 million in Q4 2025 for Avanos Medical, down from $7.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $11.0 million in Q2 2025 to a low of -$10.7 million in Q4 2021.
  • Historically, Capital Expenditures has averaged $2.5 million across 5 years, with a median of $4.4 million in 2021.
  • Biggest five-year swings in Capital Expenditures: fell 29.31% in 2022 and later skyrocketed 193.24% in 2025.
  • Year by year, Capital Expenditures stood at -$10.7 million in 2021, then rose by 1.87% to -$10.5 million in 2022, then increased by 19.05% to -$8.5 million in 2023, then grew by 12.94% to -$7.4 million in 2024, then surged by 193.24% to $6.9 million in 2025.
  • Business Quant data shows Capital Expenditures for AVNS at $6.9 million in Q4 2025, $7.0 million in Q3 2025, and $11.0 million in Q2 2025.